How smoking affects COVID-19 risk and outcomes
Current evidence indicates that smoking increases the risk of severe COVID-19 and may impair immune defense and lung function. This evergreen explainer summarizes what is known about smoking and COVID-19, describes biological mechanisms, compares risks across product types, and outlines practical steps for people who smoke who want to reduce harm. It is designed as a long-term reference rather than time-sensitive news.
Key facts at a glance
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Risk of severe COVID-19 | Higher among current smokers versus non-smokers | Systematic reviews and cohort studies |
| Severity gradient | Current smoking > former smoking > never smoking | Multivariable analyses adjusting for comorbidities |
| Vaccine response | May be modestly reduced in current smokers | Immunobiology and observational data |
| Quit timeline benefit | Risk declines after quitting, with measurable improvements over months to years | Longitudinal quit studies |
| Combustion products | Smoking delivers inhaled toxins that can impair airway immunity | Toxicology and clinical studies |
Smoking and susceptibility to SARS-CoV-2
Smoking affects respiratory mucosal barriers and systemic immune responses, which can influence susceptibility and progression of infections including COVID-19. The inhalation of smoke causes airway inflammation and may increase expression of ACE2 receptors, proteins the virus uses to enter cells. These changes create a biological environment that may facilitate initial infection and subsequent viral replication, particularly in the upper and lower airways.
Respiratory tract defenses compromised
Cilia and mucus clearing mechanisms are disrupted by tobacco smoke, reducing the ability to trap and expel pathogens. Smoking also impairs immune cell function in the lungs, including macrophages and neutrophils, limiting early viral control. These effects raise the likelihood that an exposed person will develop symptomatic infection, though multiple host and virus factors determine outcomes.
Disease severity and clinical outcomes
Multiple observational studies and meta-analyses consistently find that current smokers face a higher risk of hospitalization, intensive care admission, mechanical ventilation, and death related to COVID-19 compared with never smokers. Former smokers generally show lower risk than current smokers, indicating that stopping reduces population-level harm over time.
Severity by smoking status
- Current smoking: consistently associated with increased odds of severe disease and mortality
- Former smoking: intermediate risk that declines after quitting
- Never smoking: lowest observed risk in comparable studies
Vaping, nicotine products, and COVID-19
Evidence on vaping is less extensive than for combustible tobacco, but biological concerns exist. Aerosol exposure can induce airway inflammation and may affect ACE2 expression, potentially influencing virus entry and replication. Some surveys link vaping to respiratory symptoms that could complicate COVID-19, though population-level data remain limited. Nicotine replacement therapy under medical guidance is a less harmful option than continued smoking.
Vaccination, treatments, and smoking
Current smokers may exhibit a somewhat blunted immune response to COVID-19 vaccines, leading to lower antibody levels compared with non-smokers after certain doses. However, vaccination still substantially lowers the risk of severe disease, and boosters generally restore protection. Treatments such as antivirals and monoclonal antibodies remain effective in most smokers, though some conditions may affect drug metabolism or access to care.
Practical steps to reduce risk for people who smoke
Quitting smoking yields clear, progressive benefits for respiratory health and COVID-19 outcomes. Combining counseling, pharmacotherapy (such as nicotine replacement or prescription medications), and social support improves success rates. Until quitting is achieved, smokers can adopt lower-risk behaviors: mask in crowded indoor settings, improve ventilation, maintain distance from vulnerable contacts, and stay up to date with vaccinations and boosters.
When to seek care
Smokers who develop symptoms such as persistent fever, worsening cough, shortness of breath, or low oxygen levels should seek medical attention promptly. Early use of proven treatments can reduce progression to severe disease. Clinicians should document smoking status to tailor monitoring and consider comorbidities such as cardiovascular and pulmonary conditions when planning care.
Frequently asked questions
- Does smoking increase the chance of needing intensive care for COVID-19? Yes, current smokers have higher odds of severe outcomes compared with non-smokers, with risk decreasing after quitting.
- Are vaccines less effective for people who smoke? Vaccine-induced immunity may be somewhat reduced in current smokers, but protection against severe disease remains substantial; boosters help restore response.
- Is secondhand smoke a concern for COVID-19 risk? Secondhand smoke increases respiratory irritation and may raise susceptibility; reducing exposure is part of layered protection.
- Can quitting smoking quickly lower COVID-19 risk? Respiratory function and immune markers begin to improve within weeks to months, though long-term risk continues to decline over years.